Medtronic won FDA clearance for its Reveal LINQ Insertable Cardiac Monitor with TruRhythm Detection. The device is used to spot and analyze difficult to diagnose arrhythmias over periods as long as three years. It is an upgrade of the original Reveal LINQ, now sporting algorithms that significantly reduce the number of false positive cases of atrial fibrillation, bradycardia, and false pause episodes.
About as tall as a standard AAA, it is much thinner and is only about a third of its volume. It is implanted in the chest, just under the skin, not too far from the heart. The device continuously monitors the heart and uploads its data regularly to Medtronic’s CareLink network via an at-home bedside monitor. These reading can then be easily accessed and reviewed by the patient’s cardiologist at just about any time. The device also comes with an available Patient Assistant, which allows the person implanted with the device to mark troubling events, such as palpitations or chest pain, so that the cardiologist can correlate them with the data from the monitor.
Since patients at risk for cardiac arrhythmias often undergo MRI scans for related and unrelated conditions, the Reveal LINQ with TruRhythm has been made MR-Conditional, meaning patients can still receive magnetic resonance scans if certain precautions are taken.